Non-ST-elevation myocardial infarction outcomes in patients with type 2 diabetes with non-obstructive coronary artery stenosis: Effects of incretin treatment

Diabetes, Obesity and Metabolism

Volumn 20, Issue 3, 2018, Pages 723-729

  Marfella, Raffaele ^a   Sardu, Celestino ^a   Calabrò, Paolo ^a   Siniscalchi, Mario ^b   Minicucci, Fabio ^b   Signoriello, Giuseppe ^a   Balestrieri, Maria L ^a   Mauro, Ciro ^b   Rizzo, Maria R ^a   Paolisso, Giuseppe ^a   Barbieri, Michelangela ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b CARDARELLI HOSPITAL   (Italy)

Author keywords

antidiabetic drug; cardiovascular disease; incretin therapy

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INCRETIN; ANTIDIABETIC AGENT;

ACUTE CORONARY SYNDROME; ADULT; ALL CAUSE MORTALITY; ARTICLE; CARDIOVASCULAR MORTALITY; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; DRUG EFFECT; FEMALE; FOLLOW UP; HEART DEATH; HEART FAILURE; HEART PROTECTION; HOSPITAL READMISSION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NON OBSTRUCTIVE CORONARY ARTERY STENOSIS; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PROGNOSIS; RECURRENT DISEASE; TREATMENT DURATION; TREATMENT OUTCOME; AGED; DIABETIC ANGIOPATHY; KAPLAN MEIER METHOD; PROSPECTIVE STUDY;

AGED; CORONARY STENOSIS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NON-ST ELEVATED MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 85041862231     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.13122     Document Type: Article

References (15)

1. Pasupathy S, Air T, Dreyer RP, Tavella R, Beltrame JF. Systematic review of patients presenting with suspected myocardial infarction and nonobstructive coronary arteries. Circulation. 2015;131:861–870.
2. Planer D, Mehran R, Ohman EM, et al. Prognosis of patients with non-ST-segment-elevation myocardial infarction and nonobstructive coronary artery disease: propensity-matched analysis from the acute catheterization and urgent intervention triage strategy trial. Circ Cardiovasc Interv. 2014;7:285–293.
3. Scheen AJ. Cardiovascular outcome studies with incretin-based therapies: comparison between DPP-4 inhibitors and GLP-1 receptor agonists. Diabetes Res Clin Pract. 2017;127:224–237.
4. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2009;32(suppl 1):S62–S67.
5. Anderson JL, Adams CD, Antman EM, et al. 2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction. J Am Coll Cardiol. 2013;61:e182–e365.
6. Maddox TM, Stanislawski MA, Grunwald GK, et al. Nonobstructive coronary artery disease and risk of myocardial infarction. JAMA. 2014;312:1754–1763.
7. Blanke P, Naoum C, Ahmadi A, et al. Long-term prognostic utility of coronary CT angiography in stable patients with diabetes mellitus. JACC Cardiovasc Imaging. 2016;9:1280–1288.
8. Rana JS, Dunning A, Achenbach S, et al. Differences in prevalence, extent, severity, and prognosis of coronary artery disease among patients with and without diabetes undergoing coronary computed tomography angiography: results from 10,110 individuals from the CONFIRM (COronary CT Angiography EvaluatioN For Clinical Outcomes): an InteRnational Multicenter Registry. Diabetes Care. 2012;35:1787–1794.
9. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–242.
10. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–1335.
11. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–1326.
12. Atkin SL, Katsiki N, Banach M, Mikhailidis DP, Pirro M, Sahebkar A. Effect of dipeptidyl peptidase-4 inhibitors on circulating tumor necrosis factor-α concentrations: a systematic review and meta-analysis of controlled trials. J Diabetes Complications. 2017;31(9):1458–1464.
13. Rizzo MR, Barbieri M, Marfella R, Paolisso G. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care. 2012;35(10):2076–2082.
14. Chen WR, SY H, Chen YD, et al. Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am Heart J. 2015;170(5):845–854.
15. Balestrieri ML, Rizzo MR, Barbieri M, et al. Sirtuin 6 expression and inflammatory activity in diabetic atherosclerotic plaques: effects of incretin treatment. Diabetes. 2015;64:1395–1406.